Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OR-812
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : NIDDK
Deal Size : $1.7 million
Deal Type : Funding
Orphagen Receives NIH Funding to Advance Inflammatory Bowel Disease Drug
Details : The funding will support the development of the small molecule OR-812, a selective nuclear receptor antagonist, as a novel oral therapeutic for treatment of ulcerative colitis and Crohn’s disease
Product Name : OR-812
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 09, 2024
Lead Product(s) : OR-812
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : NIDDK
Deal Size : $1.7 million
Deal Type : Funding
Lead Product(s) : OR-449
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OR-449 is a selective, first-in-class, potent and orally bioavailable small molecule antagonist to SF-1 or NR5A1, which is essential for the growth and development of adrenal gland. It is being developed for ACC and other cancers known to express a high ...
Product Name : OR-449
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : OR-449
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OR-449
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orphagen Pharmaceuticals Presents Data on Downstream Targets of SF-1 Antagonist OR-449 at ENDO 2022
Details : OR-449 is a potent, selective, and orally bioavailable small molecule antagonist to steroidogenic factor-1 (SF-1 or NR5A1), a nuclear receptor and a transcription factor essential for the growth and development of the adrenal gland.
Product Name : OR-449
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 06, 2022
Lead Product(s) : OR-449
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OR-449
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OR-449, a potent SF-1 antagonist exhibits striking anti-proliferative activity in the rat Leydig tumor cell (LCT) line R2C, inhibiting DNA synthesis by >90% at 1 mM with an estimated IC50 of 68 nM.
Product Name : OR-449
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : OR-449
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
